Evaluation of Strategies for Use of Acellular Pertussis Vaccine in Adolescents and Adults: A Cost-Benefit Analysis

Purdy, Kenneth W.; Hay, Joel W.; Botteman, Marc F.; Ward, Joel I.
July 2004
Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, p20
Academic Journal
Pertussis is increasingly recognized as a source of infection in adults who then commonly infect young children. Immunity to illness caused by Bordetella pertussis is not long-lived, so optimal control of pertussis may require booster immunizations. In a cost-benefit analysis, we evaluated the benefits of 7 independent strategies for administering a pertussis booster, in the form of a diphtheria-tetanus-acellular pertussis vaccine, to adolescents and adults. Break-even vaccine costs for each strategy were calculated by dividing costs preventable by vaccine by the number of persons eligible for vaccination. Of these strategies, the most economical would be to immunize adolescents 10-19 years of age, which would prevent 0.7-1.8 million pertussis cases and save $0.6- $1.6 billion over a decade. Although justified by our analysis, routine adult booster vaccinations every decade would be more expensive and more difficult to implement. A recommendation for booster vaccinations every 10 years requires more information about duration of immunity, program costs, compliance, and nonmedical costs associated with pertussis.


Related Articles

  • Bordetella pertussis, Finland and France. Caro, Valérie; Elomaa, Annika; Brun, Delphine; Mertsola, Jussi; Qiushui He; Guiso, Nicole; Caro, Valérie; He, Qiushui // Emerging Infectious Diseases;Jun2006, Vol. 12 Issue 6, p987 

    We used pulsed-field gel electrophoresis analysis and genotyping to compare clinical isolates of Bordetella pertussis recovered since the early 1990s in Finland and France, 2 countries with similar histories of long-term mass vaccination with whole-cell pertussis vaccines. Isolates from both...

  • Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003. Byrne, Shane; Slack, Andrew T // BMC Infectious Diseases;2006, Vol. 6 Issue 1, p1 

    Background: In Australia two acellular Bordetella pertussis vaccines have replaced the use of a whole cell vaccine. Both of the licensed acellular vaccines contain the following three components; pertussis toxoid, pertussis filamentous haemagglutinin and the 69 kDa pertactin adhesin. One vaccine...

  • Pertussis: Challenges Today and for the Future. Cherry, James D. // PLoS Pathogens;Jul2013, Vol. 9 Issue 7, p1 

    The author argues in favor of the development of live attenuated vaccines for pertussis. He discusses the possible causes of resurgence of pertussis as well as misconceptions about Bordetella pertussis infection and disease. He believes that a high priority should be given to the development of...

  • Diphtheria-Tetanus-Acellular Pertussis Vaccine Adsorbed (Triacelluvaxâ„¢; DTaP3-CB): A Review of its Use in the Prevention of Bordetella pertussis Infection. Matheson, A.J.; Goa, K.L. // Pediatric Drugs;Mar/Apr2000, Vol. 2 Issue 2, p139 

    DTaP3-CB (Triacelluvaxâ„¢) is an acellular pertussis (aP) vaccine containing 3 antigens from purified Bordetella pertussis bacteria combined with diphtheria and tetanus toxoids (DT). In addition to purified filamentous haemagglutinin and pertactin, DTaP3-CB contains pertussis toxin which has...

  • Pertussis outbreak in university students and evaluation of acellular pertussis vaccine effectiveness in Japan. Megumi Hara; Mami Fukuoka; Katsuya Tashiro; Iwata Ozaki; Satoko Ohfuji; Kenji Okada; Takashi Nakano; Wakaba Fukushima; Yoshio Hirota // BMC Infectious Diseases;2015, Vol. 15 Issue 1, p1 

    Background: Recent studies worldwide have reported increasing numbers of adults diagnosed with Bordetella pertussis despite receiving childhood vaccinations. This study describes a pertussis outbreak at a university medical faculty campus and examines the effectiveness of diphtheria, tetanus,...

  • Manifestations of Pertussis in Immunized Children and Adults. Kirchner, Jeffrey T. // American Family Physician;11/1/1999, Vol. 60 Issue 7, p2148 

    Provides information on the prevalence and incidence of Bordetella pertussis (B. pertussis) infections in adults. Clinical presentation and course of B. pertussis infection among immunized persons; Diagnosis and treatment of B. pertussis infection.

  • Whooping cough vaccine `should be replaced'. Brown, Phyllida // New Scientist;10/23/93, Vol. 140 Issue 1896, p7 

    Reports on the use of acellular vaccines as replacement for whooping cough vaccine or pertussis. Existing whole-cell vaccine based on a suspension of the whole, killed bacterium, Bordetella pertussis; Limitations of the United States Food and Drug Administration-licensed acellular vaccine.

  • Reactions after pertussis vaccine: a manufacturer's experiences and difficulties since 1964. Griffith, A.H. // British Medical Journal;4/1/1978, Vol. 1 Issue 6116, p809 

    Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all...

  • Editorial Commentary: Accounting for Pertussis. DeMaria, Alfred // Clinical Infectious Diseases;Jun2012, Vol. 54 Issue 12, p1736 

    An introduction is presented in which the editor discusses the article on pertussis vaccines.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics